Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SVRE vs MLAB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLAB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

MLAB Overall Winner 6-Pillar Tally: SVRE 0 – 5 MLAB (1 Tie) Matrix Metrics: SVRE 0 – 10 MLAB

As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over SaverOne 2014 Ltd. (SVRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SVRE carries a Unified Composite Score of 39.3/100 (SELL) at $0.43 (N/M Forward P/E, 0.0% operating margin), whereas MLAB carries 41.6/100 (SELL) at $135.27 (24.9x Forward P/E, 10.4% operating margin).

  • Defensive Composite Rating Caution: Although MLAB compares more favorably head-to-head, both SVRE (39.3/100 SELL) and MLAB (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: SVRE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile MLAB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SVRE vs MLAB
SVRE NASDAQ
SaverOne 2014 Ltd. American Depositary Shares
Services-Computer Programming Services
$0.43
-1.46% 1D
Market Cap $1.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 0.49β · 190% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.4%), weak momentum, RSI 28
RSI-14: 28.4 · SMA20: $0.89 · SMA50: $1.47
MLAB NASDAQ Head-to-Head Winner
Mesa Laboratories Inc
Industrial Instruments For Measurement, Display, And Control
$135.27
+0.88% 1D
Market Cap $781.3M
TTM Revenue $251M
Forward P/E 24.9x
Beta / 30D Vol 1.14β · 54% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 20.0 Fund 32.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.1% over 20 days), RSI 54
RSI-14: 54.3 · SMA20: $129.84 · SMA50: $129.16

6-Pillar Scorecard Institutional Category Breakdown (SVRE 0 – 5 MLAB)

Columns: Metric · SVRE · MLAB
1. Valuation Multiples MLAB
Forward P/E N/M 24.9x
Trailing P/E N/M 119.8x
PEG Ratio N/M N/M
EV / Revenue 0.6x 3.1x
2. Growth & Scale MLAB
Revenue Growth (YoY) -63.0% +2.6%
Earnings Growth (YoY) +0.0% +67.0%
TTM Revenue (USD) $2.0M $251M
Market Cap $1.1M $781.3M
3. Profitability & Quality MLAB
Gross Margin -41.1% 64.8%
Operating Margin 0.0% 10.4%
Net Profit Margin 0.0% 2.6%
Return on Equity (ROE) -151.1% 3.6%
4. Balance Sheet & Cash Flow MLAB
Cash Generation (TTM) -$34M EBITDA $49M EBITDA
Cash Flow Margin N/A 19.4% EBITDA Mgn
Net Cash / Leverage $0.00 Book/Sh · -151.1% ROE $34.66 Book/Sh · 3.6% ROE
Dividend Yield None (0.00%) 0.47%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat MLAB
OpEx & R&D Intensity N/A 54.4% of Rev ($137M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Scientific & Technical Instruments Operator Scientific & Technical Instruments Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SVRE (0) vs MLAB (10)
Institutional Metric SVRE MLAB Criterion Row Edge
Market Capitalization
Scale
$1.1M $781.3M Larger Scale MLAB
Trailing P/E Ratio
Valuation
N/M 119.8x Lower Multiple MLAB
Forward P/E Ratio
Valuation
N/M 24.9x Lower Multiple MLAB
Revenue Growth (YoY)
Growth
-63.0% +2.6% Higher Growth MLAB
Operating Margin (TTM)
Profitability
0.0% 10.4% Higher Margin MLAB
Net Profit Margin
Profitability
0.0% 2.6% Higher Margin MLAB
Return on Equity (ROE)
Capital Efficiency
-151.1% 3.6% Higher ROE MLAB
52-Week Range Position
Momentum
0% ($0–$6) 88% ($70–$144) Stronger Trend MLAB
Beta / 30D Volatility
Risk Regime
0.49β · 190% Vol 1.14β · 54% Vol Lower Realized Risk MLAB
Unified Institutional Score
Composite Signal
39.3 / 100 (SELL) 41.6 / 100 (SELL) Higher Composite MLAB
Trailing 12M Revenue (USD)
Operating Scale
$2.0M $251M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-41.1% 64.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$34M EBITDA ($0.00 Book/Sh · -151.1% ROE) $49M EBITDA ($34.66 Book/Sh · 3.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLAB +85.95 pp
SVRE: -76.25% · MLAB: +9.7%
3M Horizon MLAB +98.07 pp
SVRE: -85.08% · MLAB: +12.99%
6M Horizon MLAB +125.05 pp
SVRE: -89.55% · MLAB: +35.5%
1Y Horizon MLAB +139.6 pp
SVRE: -56.66% · MLAB: +82.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SVRE vs MLAB. Trailing 12-month operating profitability (SVRE 0.0% vs MLAB 10.4%) and valuation multiples (SVRE N/M vs MLAB 24.9x Forward P/E) are benchmarked directly in Pillar 4 below.

SVRE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.0M
Gross Margin-41.1%
Op. Margin0.0%
ROE / Fwd P/E-151.1% · N/M
MLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$251M
Gross Margin64.8%
Op. Margin10.4%
ROE / Fwd P/E3.6% · 24.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SVRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SVRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SVRE Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $1.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MLAB Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $781.3M market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($137M)
90D Engineering Disclosures 0 Published

Investor FAQ SVRE vs MLAB Key Questions & Quantitative Answers

As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over SaverOne 2014 Ltd. (SVRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SVRE carries a Unified Composite Score of 39.3/100 (SELL) at $0.43 (N/M Forward P/E, 0.0% operating margin), whereas MLAB carries 41.6/100 (SELL) at $135.27 (24.9x Forward P/E, 10.4% operating margin). Defensive Composite Rating Caution: Although MLAB compares more favorably head-to-head, both SVRE (39.3/100 SELL) and MLAB (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SVRE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile MLAB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MLAB leads the Growth & Scale pillar: SVRE posts -63.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (-41.1% gross margin, 0.0% operating margin), compared with MLAB at +2.6% YoY revenue growth and +67.0% YoY earnings growth on $251M TTM revenue (64.8% gross margin, 10.4% operating margin). On trailing 12-month operating scale, SVRE generates $2.0M in USD-normalized revenue versus $251M for MLAB. In operating R&D and SG&A reinvestment, SVRE deploys N/A (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($137M) (0 disclosures) for MLAB.

MLAB screens cheaper on headline valuation multiples. SVRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (unreported EBITDA margin), whereas MLAB trades at 24.9x Forward P/E, 119.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (19.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SVRE (-151.1% ROE) versus MLAB (3.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SVRE carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 190% Vol realized risk). By comparison, MLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.14β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.